HISCO semi annual report: net profit increased by 61.55%, R & D investment and international business went hand in hand

In the evening of August 5, the first half of 2019 annual report of Hisilicon was published, achieving an operating revenue of 1.869 billion yuan, a year-on-year increase of 57.00%, and a net profit of 235 million yuan, a year-on-year increase of 61.55% The rapid growth of net profit is due to the transformation of Hisilicon's marketing mode, the high market share of main products and the rapid growth of sales of key products With the transformation of marketing mode, the whole business of new varieties increased by 217 times over the same period of last year According to the announcement, in the first half of 2019, with the comprehensive promotion of the heavy policies such as the consistency evaluation of generic drugs, 4 + 7 volume procurement and key monitoring catalogue, Hisilicon's marketing strategy was transformed into academic led marketing, from a single investment agency model to partnership and self operating marketing model, and Beijing, Shanghai and Sichuan branches were established, while the self-supporting sales of innovative drugs were established Business department, build a new marketing system Combined with the existing product line, speed up the strong control of channel and terminal; influence experts, doctors and consumers through academic marketing and brand marketing, and shape the HISCO brand In the first half of 2019, Hisilicon's leading promotion products grew rapidly The company's key products dorasetron mesylate injection increased 259.4% year-on-year, polypristine granules increased more than 142.9% year-on-year, compound amino acid injection increased 119.7%, Flupentixol tablets, namefen salt injection, arginine glutamate injection and methylprednisolone increased more than 50% year-on-year, new The total sales of varieties increased 217 times year on year In addition, it is worth mentioning that Hisense currently sells 35 kinds of products, most of which are domestic or exclusive imitations, involving liver disease, parenteral nutrition, depression, antibiotics and other fields, with a high market share Among them, the liver disease drug polyene phosphatidylcholine injection has entered the national medical insurance category B product catalog, covering more than 4000 hospitals above the second level; the same kind of products occupy 100% of the market share, and HISCO is the only enterprise selling the same kind of products in China; the fat soluble vitamins for injection (II) / water soluble vitamins for injection rank first in the sales and market share of the same kind of products, Accounted for 91.62% of the market share; compound amino acid injection (18aa-vii) is the new fourth generation of therapeutic amino acid, ranking first in sales and market share among the same varieties, and has entered the national medical insurance class B, covering nearly 3000 hospitals, accounting for 72.30% of the market share; and dorasetron mesylate injection, national medical insurance class B, accounting for 100% of the market share of the same kind In the first half of 2019, Hisense increased its R & D investment According to the announcement, in the first half of 2019, Hisense invested about RMB 229 million in R & D, up 67.36% year on year At present, there are 68 pharmaceutical research and development projects of HISCO, including 58 generic drugs, 7 innovative drugs, 2 biological drugs and 1 formula food for special medical purposes; it mainly involves 4 treatment fields, including 27 digestive tract and metabolism, 6 nervous system, 6 respiratory system, 9 cardiovascular system and 20 other fields; among them, there are 5 new application projects in the first half of 2019 Schedule of major generic drug projects under development schedule of new drug R & D In addition, in the first half of the year, hispec was also active in preparing for the consistency evaluation There were two varieties that passed or deemed to pass the consistency evaluation, namely, flupentixol-t-melitracen tablets and tenofovir-dipivoxil-fumarate tablets Among them, tenofovir-dipivoxil fumarate tablets were classified into four categories of new chemicals and obtained the production approval, and deemed to pass the consistency evaluation According to the statistics of drug registration and acceptance database, up to now, there are 5 declared varieties for consistency evaluation of Hisilicon, including 4 for injection, and 2 for supplementary application The details are shown in the following table: details of consistency evaluation of Hisilicon's declaration and acceptance to expand international cooperation and enhance R & D strength While focusing on R & D and transformation of marketing mode to improve performance, Hisense has also actively expanded its business and cooperation In the first half of this year, Hisense completed two international cooperation businesses: in July, Hisense signed the "development" on aripitan capsule with India's fourth largest pharmaceutical company, glenmark pharmaceuticals limited, License & supply agreement, which is the exclusive manufacturing and supply of this product for Hisense Hisense purchases this product exclusively from glenmark and uses it for commercialization in mainland China HISCO is responsible for the registration, application and sales of the product in mainland China In April, Hisense agreed to sign stock purchase agreement and exclusive license agreement between Sichuan Hisense, a wholly-owned subsidiary of Hisense, and exithera, a U.S company, to use US $6 million to subscribe 2787068 ordinary shares issued by exithera, and obtain the exclusive license of ep-7041 in China It is reported that Sichuan Hisense has obtained the exclusive license of the ep-7041 product of exithera in mainland China Sichuan Hisense has the right to carry out clinical research, registration, declaration, production, marketing and other commercial rights and interests in the above-mentioned license areas Exithera company will obtain 8% of the total sales revenue of the Chinese market in the future, with a term of 10 years or until its patent expires in the authorized field Through cooperation with pharmaceutical companies with international level, Hisense has opened up a new business model, improved its R & D strength of new drugs, effectively enriched the company's product line, and improved its competitiveness Source: Internet public information statement such as yaozhi.com and enterprise announcement: the viewpoint of this article only represents the author, not the position of yaozhi.com You are welcome to exchange and supplement in the message area If you need to reprint, please be sure to indicate the author and source of the article.